Microbiome Therapeutics Articles & Analysis
48 news found
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
Funds to support scale-up, including continued development of AI-augmented knowledge discovery platform, the e[datascientist]™, and continued international expansion Platform business focused on bridging the current ‘translation gap’, addressing critical bottlenecks in the industrial application of microbiome science – from soil, to plant, to farm, to fork, to human, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of preclinical data supporting further investigation of a rationally designed microbial consortium candidate (DE486) to prevent or treat gastrointestinal (GI) mucositis – a common and often painful complication of radiation and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections (rCDI) by rapidly establishing a long-lasting colony of beneficial gut microbes, which can ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 18, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. “Seres continued to make important progress toward bringing SER-109 to patients suffering with recurrentC. difficileinfection (rCDI). Given the robust profile of SER-109 ...
SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that the U.S. Food and Drug Administration (FDA) has ...
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis process for academia and pharma researchers and is setting the ...
ByBio-Me
As part of our growth and consolidation as a microbiome company focused on therapeutics we have several openings to join our team! Are you ready to rock? Check out our careers section and submit your credentials: Microviable careers ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). The project, to support the ongoing development of Microbiotica’s Live Bacterial Therapeutic (LBT) ...
Our Founder & CEO Dr James McIlroy was recently featured on The Pharma Letter podcast with Simon Wentworth discussing mastering the microbiome. James discusses how EnteroBiotix is developing its pipeline of highly diverse microbiome enhancing therapeutics through a unique approach to development and manufacturing, focussed on supply chain control and novel technologies. Listen here to ...
Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. The international investment syndicate was co-led by Flerie Invest, a major Swedish life science investor focussing on companies ...
Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics, today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grant will provide funding for the continued ...
Dr. Ryan Gordon has joined the Stem Pharm team as Sr. V.P. of Business Development and Commercialization. Gordon brings to Stem Pharm over 20 years of business, R&D, and operational experience in developing and commercializing innovative biopharmaceutical technologies to revolutionize disease treatment and improve patient outcomes. He has been a valued leader at large companies (3M) and ...
Advancement of first program from Axial platform into a randomized Phase 2b clinical trial signifies key milestone for company Trial is enrolling approximately 195 autistic adolescents at clinical trial sites in the United States, Australia and New Zealand Phase 2 trial is based on positive results from open-label Phase 1b/2a trial that demonstrated a favorable safety profile for AB-2004 as ...
Global, placebo-controlled Phase 2b trial now enrolling in the U.S., Australia and New Zealand Axial is activating 20 Phase 2b clinical trial sites in the U.S. and seven clinical sites in Australia and New Zealand Clinical studies to date confirm AB-2004’s strong safety profile and potential to address large unmet treatment need in irritability associated with autism spectrum disorder ...
Proceeds will support Axial's randomized, controlled Phase 2b clinical trial for lead candidate, AB-2004, a molecular therapeutic to treat irritability in children with autism Funding positions company for platform and pipeline growth Completion of new round brings total investment in company to $91.5 million to date Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated ...
High-dose VE303 in Phase 2 trial achieved primary endpoint, with 31.7% absolute risk reduction in rate of recurrence (or a greater than 80% reduction in the odds of a recurrence) at 8 weeks when compared with placebo Represents most advanced clinical trial of a rationally defined bacterial consortium candidate BARDA exercises $23.8 million option to support Phase 3 clinical trial of VE303, to ...
LISCure Biosciences ("LISCure") announced that it has received approval for a global phase 1 clinical trial for two programs, LB-P6 and LB-P8, targeting autoimmune disease and non-alcoholic steatohepatitis (NASH), respectively. This achievement is significant in that it will be the first global clinical trial among the microbiome treatments for rheumatoid arthritis and NASH indications. The most ...